2
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Lymphoid
1
Genitourinary
1
CNS
1
Conditions
Prostatic Neoplasms
8
Breast Neoplasms
4
Pancreatic Neoplasms
3
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Urinary Bladder Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Lung Neoplasms
2
Kidney Neoplasms
2
Carcinoma, Renal Cell
2
Wilms Tumor
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Sarcoma
1
Rhabdomyosarcoma
1
Rectal Neoplasms
1
Pain
1
Neuroectodermal Tumors, Primitive
1
Neuroblastoma
1
Neoplasms, Germ Cell and Embryonal
1
Medulloblastoma
1
Lymphoma, Non-Hodgkin
1
Lymphoma
1
Hodgkin Disease
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Brain Neoplasms
1
Interventions
Cisplatin
13
Etoposide
11
Paclitaxel
8
Cyclophosphamide
7
Carboplatin
7
Ifosfamide
6
etoposide phosphate
5
Granulocyte Colony-Stimulating Factor
5
Gemcitabine
5
pembrolizumab
4
fludarabine
4
Sirolimus
4
Bleomycin
4
fludarabine phosphate
3
Sunitinib
3
Oxaliplatin
3
Mesna
3
Melphalan
3
Filgrastim
3
Drug Therapy
3
Brentuximab Vedotin
3
Bevacizumab
3
Automobiles
3
130-nm albumin-bound paclitaxel
3
tremelimumab
2
sodium thiosulfate
2
ribociclib
2
pralsetinib
2
pegfilgrastim
2
lutetium Lu 177 dotatate
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms, Germ Cell and Embryonal
×
Genistein
×
Clear all
NCT02624388
2024-05-06
UVA-Gen001
University of Virginia
Phase 2
Terminated
4 enrolled
16 charts